Early Detection, Prognosis Prediction, and Recurrence Monitoring of Lung Cancer Possible with a Single Urine Sample: Highly Accurate Lung Cancer Detection Using Urinary MicroRNA and AI
NQ Score
92/100
N1 Content Completeness
95
AI Summary (NQ-processed)
Craif Inc., a bio-AI startup, in collaboration with Tokyo Jikei University School of Medicine and Higashiosaka City Medical Center, has developed a non-invasive testing platform that enables early detection, prognosis prediction, and recurrence monitoring of lung cancer using urinary microRNA and AI. This research, published in "npj Precision Oncology" on April 18, 2026, allows for home urine collection and is expected to be applied to widespread screening.